Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

The Original Article was published on 17 December 2020

Correction to: Nature Medicine https://doi.org/10.1038/s41591-020-01179-4, published online 17 December 2020.

In the version of this article initially published, the numbers of cells in the third sentence of the second paragraph of the Methods subsection ‘Antibody-dependent neutrophil phagocytosis’ (500,000) and in the fifth sentence of the first paragraph of the Methods subsection ‘Antibody-dependent monocyte phagocytosis’ (250,000) were incorrect. The correct numbers are 50,000 and 25,000 (respectively). The errors have been corrected in the HTML and PDF versions of the article.

Author information

Affiliations

Authors

Consortia

Corresponding authors

Correspondence to Daniel Jenkin or Andrew J. Pollard.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Barrett, J.R., Belij-Rammerstorfer, S., Dold, C. et al. Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med (2021). https://doi.org/10.1038/s41591-021-01372-z

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing